Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has issued an update.
Shanghai Junshi Biosciences Co., Ltd. reported a significant increase in operating revenue for 2024, reaching approximately RMB1,949 million, a 29.71% increase compared to the previous year. Despite this, the company still faced a net loss of approximately RMB1,292 million, indicating improvements with a 43.42% decrease in losses from the previous year. The increase in revenue is attributed to the improved sales efficiency, increased product indications, and expanded international market presence, particularly for its core product, Toripalimab.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a pharmaceutical company based in China, focusing on the development and commercialization of innovative drugs. The company is involved in developing treatments such as Toripalimab Injection, Adalimumab Injection, Deuremidevir Hydrobromide Tablets, and Ongericimab Injection, with a market focus on expanding their global commercialization network.
YTD Price Performance: -7.25%
Average Trading Volume: 1,273,893
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$23.43B
See more insights into 1877 stock on TipRanks’ Stock Analysis page.
